ImmuCell's Two-Product Edge in Cattle Health Fuels Growth

ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.

Zacks Investment Research • Dec 4, 2025

ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength

ImmuCell tumbles despite stronger margins and a rebound in EPS, as backlog dynamics pressure quarterly sales while management highlights improving operations.

Zacks Investment Research • Nov 20, 2025

ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript

ImmuCell Corporation ( ICCC ) Q3 2025 Earnings Call November 14, 2025 9:00 AM EST Company Participants Michael Brigham - Special Advisor to the CEO & Director P. F. Te Boekhorst - President, CEO & Director Timothy Fiori - CFO, Secretary, Treasurer & Director Conference Call Participants Joe Diaz - Lytham Partners, LLC Frank Gasca George Melas - MKH Management Company, LLC Presentation Operator Good morning, and welcome to the ImmuCell Corporation Reports Third Quarter ended September 30, 2025, Unaudited Financial Results Conference Call.

Seeking Alpha • Nov 14, 2025

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025.

GlobeNewsWire • Nov 13, 2025

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. The Company is planning to host a conference call the next morning, Friday, November 14, 2025, at 9:00 AM ET to review the unaudited financial results.

GlobeNewsWire • Nov 6, 2025

ImmuCell Announces Onboarding of New CEO and Related Management Changes

PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes.

GlobeNewsWire • Nov 4, 2025

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025.

GlobeNewsWire • Oct 7, 2025

ImmuCell Announces Selection of its Next President and CEO

PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst.

GlobeNewsWire • Sep 29, 2025

ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide

ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.

Zacks Investment Research • Aug 21, 2025

ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript

ImmuCell Corporation (NASDAQ:ICCC ) Q2 2025 Earnings Conference Call August 15, 2025 9:00 AM ET Company Participants Michael F. Brigham - President, CEO, Treasurer, Secretary & Director Timothy C.

Seeking Alpha • Aug 15, 2025